National Institute on Drug Abuse - Intramural Research Program
FARESHARE: An open-source apparatus for assessing drinking microstructure in socially housed rats. NPP—Digit Psychiatry Neurosci.
The authors describe an open-source and cost-effective system for monitoring drinking behavior in group housed rodents. The fully customizable system can measure both the volume consumed and drinking bouts microstructure in context of social behaviors.
[Read More]
Featured Paper of the Month – May 2024
Xylazine, an increasingly abused drug mixed with fentanyl, leads to devastating respiratory issues during fentanyl-xylazine overdose. Despite naloxone being the primary treatment, it falls short in fully reversing the hypoxic effects of the drug mixture. Our study suggests that supplementing naloxone with atipamezole, a xylazine antagonist, provides a more effective and thorough solution for addressing brain hypoxia caused by fentanyl-xylazine mixture.
Hot Off the Press – April 24, 2024 Published in Molecular Psychiatry by Atul Daiwile and Jean Lud Cadet, et al. from the NIDA IRP Molecular Neuropsychiatry Section. Summary Methamphetamine also called METH, crank, ice etc. is a powerful stimulant that has caused addiction in a lot of people in the world. Humans who take… [Read More]
Congratulations to the NIDA labs who participated and received awards in the 2023 NIH Green Labs Program! Molecular Neuropsychiatry Section, Adjei, Nasser – Gold Translational Analytical Core, Kryszak, Lindsay – Silver Neuronal Circuits and Behavior Section, Sarsfield, Sarah – Silver Integrative Neuroscience Research Branch, Neuronal Networks Section, Barbano, Flavia – Bronze Molecular Targets and Medications… [Read More]
Hot Off the Press – April 18, 2024 Published in The Journal of Neuroscience by Jonathan Chow, Kayla Pitts and Yavin Shaham, et al. from the NIDA IRP Neurobiology of Relapse Section. Summary Recent studies have shown that when rats are given a mutually exclusive choice between social interaction with a peer and an addictive… [Read More]
Hot Off the Press – April 10, 2024 Published in Nature Communications by Qingfang Liu and Thorsten Kahnt, et al. from the NIDA IRP Learning and Decision-Making Unit. Summary In this study, Qingfang Liu (Research Fellow in the LDMU) and colleagues show that identity prediction errors in the dopaminergic midbrain are computed based on outcome… [Read More]
Hot Off the Press – April 4, 2024 Published in Translational Psychiatry by Yi He, Hui Shen and Zheng-Xiong Xi, et al. from the NIDA IRP Addiction Biology Unit and Magnetic Resonance Imaging and Spectroscopy Section. Summary G protein-coupled receptor 55 (GPR55) is a putative cannabinoid receptor, which has been considered as the “CB3” receptor, as… [Read More]
Reviews To Read – April 2024. Published in Current Opinion in Neurobiology by Kenichiro Negishi and Yavin Shaham of the NIDA IRP Neurobiology of Relapse Section. In this review we introduce the electric barrier conflict model of drug relapse and review studies on behavioral and neuropharmacological mechanisms of cue-induced relapse and incubation of drug seeking (time-dependent… [Read More]
Featured Paper of the Month – April 2024
Published in Frontiers in Public Health by Salvatore Giorgi and Brenda Curtis, et al. of the NIDA IRP Technology and Translational Research Unit.
In this work, we apply a computational linguistic framework to measure dehumanization to 3 million news articles. We show that popular media in the U.S. has dehumanized people who used substances to varying degrees. Substances such as heroin have been strongly dehumanized for decades, while marijuana use is becoming less dehumanized over time, aligning with increased public support for legalization.
Hot Off the Press – March 26, 2024 Published in Translational Psychiatry by Khalin Nisbett, Leandro Vendruscolo and George Koob from the NIDA IRP Stress & Addiction Neuroscience Unit and Neurobiology of Addiction Section. Summary Nisbett et al. discovered that the anxiolytic-like (anxiety-reducing) effect of oxytocin can be modulated by the endogenous opioid system. We… [Read More]
